FDA reveals $94m user fee increase

Share this article:
FDA drug and biologic user fees will jump almost 30% next year—from about $300 million to almost $400 million in 2008, according to details released about the PDUFA 4 negotiations.

The agreed-upon increase, which is yet to be submitted to Congress, directs $37.9 million to fund proposed enhancements to the PDUFA program.

The remaining amount is spread among a calculated “workload adjustment” for shortcomings not projected in the previous agreement ($20 million), increased costs for moving to its consolidated campus in White Oak, MD ($11.7 million), and an inflation adjustment ($17.7 million).

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.